Physician profile
Sreenivas Kamath
NPI 1629165378
$2,648.11
in general payments reported to CMS, 2019-2025
32 companies · $625 in 2025
The $625 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $130 · 2021: $13.88 · 2022: $425 · 2023: $488 · 2024: $703 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $688.88 | 2019-2025 | |
| Medtronic, INC. | $198.61 | 2025 | Symplicity G3, Abre, Spiderfx |
| Abiomed | $190.62 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $172.23 | 2023-2025 | Lifevest |
| Pfizer INC. | $156.55 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $140.67 | 2019-2022 | |
| Philips North America LLC | $124.06 | 2022-2025 | Mcot |
| Boston Scientific Corporation | $122.00 | 2022-2025 | Watchman Flx |
| Angiodynamics, INC. | $96.25 | 2022-2024 | Auryon Laser System 100-120 Vac |
| Abbott Laboratories | $88.32 | 2022-2024 | Cardiomems |
| Shockwave Medical, INC | $78.10 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.01 | 2019-2023 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $57.20 | 2023-2024 | Inpefa |
| Imperative Care, INC | $45.77 | 2025 | Prodigy Catheter, Symphony Catheter |
| Astrazeneca Pharmaceuticals Lp | $42.46 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.15 | 2020-2024 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $35.04 | 2024 | Arcalyst |
| Veryan Medical Incorporated | $33.94 | 2024-2025 | Biomimics 3d Vascular Stent System |
| Cook Medical LLC | $33.84 | 2023-2025 | Lunderquist, Resonance |
| Regeneron Healthcare Solutions, INC. | $27.89 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.44 | 2019-2023 | Camzyos |
| Edwards Lifesciences Corporation | $25.72 | 2020 | |
| Chiesi USA, INC. | $21.59 | 2019 | |
| Teleflex LLC | $19.30 | 2025 | Vascband |
| Cardiovascular Systems INC. | $18.74 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $18.17 | 2023 | Arcalyst |
| Cardiva Medical, INC. | $17.70 | 2022 | |
| Cathworks, INC. | $14.64 | 2025 | Ffrangio |
| Cordis US Corp. | $13.85 | 2025 | Mynxgrip |
| Biotronik INC. | $13.21 | 2024 | Orsiro Mission, Pk Papyrus |
| Actelion Pharmaceuticals US, INC. | $13.16 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$150,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sreenivas Kamath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.